All Updates

All Updates

icon
Filter
Partnerships
Proscia partners with Nucleai to expand AI biomarker solutions for precision medicine
Precision Medicine
Jun 25, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Precision Medicine

Precision Medicine

Jun 25, 2024

Proscia partners with Nucleai to expand AI biomarker solutions for precision medicine

Partnerships

  • Proscia has announced a collaboration with Nucleai to expand its precision medicine AI services and help optimize clinical trials and improve treatment decisions.

  • The collaboration involves integrating Nucleai’s predictive biomarker solutions into Proscia's software platform, Concentriq, as part of its precision medicine AI portfolio. This aims to help create an AI-guided roadmap of patient biopsies, aiding laboratories in optimizing clinical trials and matching patients to effective treatments and enabling pathologists and clinicians to convert data from patient biopsies into actionable insights to support better clinical trial and diagnostic decisions, potentially advancing next-generation treatment modalities such as ADCs, multi-specifics, immunotherapy, and combination therapies. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.